SEC Filing Summary
Filing and entity: The provided Form 10-Q is for Neuralstem, Inc., not Palisade Bio, Inc.; investors should verify the issuer identity. The report covers the quarter and six months ended June 30, 2018, with unaudited results.
Business Context and Reporting Period
Neuralstem was a clinical-stage biopharmaceutical company developing neural stem-cell therapies and small-molecule compounds for central nervous system diseases. Its lead programs were NSI-189, a small molecule, and NSI-566, a neural stem-cell therapy. The company operated in one business segment and had six full-time employees as of July 31, 2018.
The company had no revenue from commercial product sales. Reported revenue primarily consisted of intellectual-property licensing fees and a $250,000 milestone-based royalty related to settlement of a prior patent-infringement case.
Financial Performance and Liquidity
| Metric | Three months ended June 30 | Six months ended June 30 |
|---|---|---|
| Revenue | $252,500, versus $2,500 in 2017 | $255,000, versus $5,000 in 2017 |
| Operating loss | $(2,022,972), versus $(4,218,231) | $(4,371,967), versus $(8,450,238) |
| Net loss | $(627,046), versus $(4,649,192) | $(2,774,014), versus $(12,216,446) |
| Loss per share | $(0.04), versus $(0.39) | $(0.18), versus $(1.06) |
| Net cash used in operating activities | Not provided for the quarter | $(4,370,431), versus $(7,807,240) |
Research and development expense was $1.0 million in the second quarter and $2.2 million for the first six months, down 61% and 60%, respectively, from the comparable 2017 periods. General and administrative expense declined 23% in the quarter and 18% year to date.
Cash and cash equivalents were $7.1 million at June 30, 2018, compared with $6.7 million at December 31, 2017. Short-term investments declined from $5.0 million to zero as certificates of deposit matured. Total assets were $9.2 million and stockholders’ equity was $6.2 million at June 30, 2018.
Current liabilities were $766,001. The balance sheet reported $2.3 million of liability-classified warrants at fair value and $8,270 of other long-term liabilities. The filing also reports $209,636 of short-term debt repayments during the first six months; the source text does not provide a clear total debt balance at June 30, 2018.
Management expected existing cash to fund operations into the first quarter of 2019, but stated that substantial doubt existed regarding the company’s ability to continue as a going concern within one year after issuance of the financial statements. No future funding commitments were in place.
Material Changes Versus the Prior Comparable Period
- Revenue increased by $250,000 in both the quarter and year-to-date periods, driven primarily by the patent-settlement milestone royalty.
- Operating expenses fell by 46% in the quarter and 45% for the first six months, reflecting restructuring, lower personnel and facility costs, completion of the NSI-189 Phase 2 trial, and reduced share-based compensation.
- Net loss improved substantially, primarily because of lower operating expenses and non-cash gains from changes in the fair value of liability-classified warrants.
- The warrant fair-value adjustment produced other income of $1.4 million in the quarter and $1.6 million year to date, compared with warrant-related losses in 2017. The warrant liability decreased from $3.9 million at year-end 2017 to $2.3 million at June 30, 2018.
- Operating cash burn improved by $3.4 million year over year, while investing cash flow benefited from the $5.0 million maturity of short-term investments.
- The company adopted the new revenue-recognition standard, Topic 606, on January 1, 2018, with no material impact reported.
Guidance, Outlook, Risks and Unusual Items
- Management did not provide formal revenue or earnings guidance. It expected continued operating losses and did not expect profitability in the next several years.
- Additional capital was expected to be required through equity or debt offerings, collaborations, licensing arrangements, grants, or a combination of these sources. Failure to obtain funding could require delaying or stopping clinical trials and research programs, curtailing operations, or seeking bankruptcy protection.
- NSI-189’s Phase 2 major-depressive-disorder trial failed to meet its primary endpoint, although certain secondary and cognitive measures were favorable. The company was seeking a partner and financial support for the program.
- NSI-566 programs in ALS, chronic stroke, and chronic spinal-cord injury reported preliminary signals of benefit and acceptable tolerability, but required additional, larger or controlled studies to establish efficacy.
- The company received a $150,000 Department of Defense SBIR award for traumatic-brain-injury development and had an approximately $1 million NIH SBIR grant for diabetic-neuropathy research. Grant reimbursements reduced reported research and development expense.
- In April 2018, the company recognized an additional approximately $50,000 loss related to subleasing its unused San Diego facility.
- The former President, Chief Executive Officer and Chief Financial Officer resigned effective July 31, 2018. An interim CEO and CFO were appointed effective August 1, 2018, creating management-transition risk.
- Key risks included clinical-trial failure or delay, regulatory non-approval, dependence on third-party manufacturers and clinical organizations, intellectual-property challenges, limited personnel, financing and dilution risk, and potential Nasdaq delisting.
- No legal proceedings were pending at the filing date, and the company reported no unregistered securities sales or defaults upon senior securities.
Investor Verification Checklist
- Confirm that the filing belongs to Neuralstem, Inc. and reconcile it with the requested Palisade Bio, Inc. issuer.
- Verify available cash, expected cash runway into the first quarter of 2019, and the company’s going-concern qualification.
- Review the composition, exercise terms, dilution potential, and fair-value sensitivity of approximately 2.98 million liability-classified warrants and other outstanding equity-linked instruments.
- Assess whether the $250,000 settlement-related royalty is recurring and distinguish it from sustainable operating revenue.
- Evaluate the clinical significance and confirmatory-study requirements for NSI-189 and NSI-566, particularly after the NSI-189 Phase 2 primary-endpoint failure.
- Review subsequent financing, partnership, management-transition, Nasdaq-listing, and clinical-development events after June 30, 2018.